Vanelslander Cancer Center Pharmacy
19229 Mack Ave, 
Grosse Pointe Woods, MI 

Overview

Adonis Lorenzana is a Hematologist and an Oncologist in Grosse Pointe Woods, Michigan. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Immune Thrombocytopenic Purpura (ITP), Classical Hodgkin Lymphoma, Bone Marrow Aspiration, and Splenectomy.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 32 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cook Children's Health Plan
  • MANAGED MEDICAID PLAN
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Vanelslander Cancer Center Pharmacy
19229 Mack Ave, Grosse Pointe Woods, MI 48236

Additional Areas of Focus

Dr. Lorenzana has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


32 Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
View 27 Less Clinical Trials
Similar Doctors
Expertise in
31
conditions
Hematology | Oncology
Expertise in
31
conditions
Hematology | Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (42.8 miles away)
Languages Spoken:
English

Kelly Walkovich is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Walkovich is highly rated in 31 conditions, according to our data. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Infantile Neutropenia, Non-Langerhans-Cell Histiocytosis, and Reticulohistiocytoma.

Expertise in
5
conditions
Hematology | Oncology
Expertise in
5
conditions
Hematology | Oncology

DMC Children's Hospital Of Michigan

3901 Beaubien St, 
Detroit, MI 
 (8.7 miles away)
Languages Spoken:
English

Emily Meier is a Hematologist and an Oncologist in Detroit, Michigan. Dr. Meier is highly rated in 5 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant.

Expertise in
8
conditions
Hematology | Oncology
Expertise in
8
conditions
Hematology | Oncology

DMC Children's Hospital Of Michigan

3901 Beaubien St, 
Detroit, MI 
 (8.7 miles away)
Languages Spoken:
English

Michael Callaghan is a Hematologist and an Oncologist in Detroit, Michigan. Dr. Callaghan is highly rated in 8 conditions, according to our data. His top areas of expertise are Hemophilia A, Blood Clots, Sickle Cell Disease, Evans Syndrome, and Splenectomy.

Frequently Asked Questions about Dr. Adonis Lorenzana

How do I make an appointment with Dr. Adonis Lorenzana?

You can book an appointment with Dr. Adonis Lorenzana by calling their office at 800-848-0202. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Adonis Lorenzana a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Adonis Lorenzana is classified as an Experienced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Adonis Lorenzana specialize in?

While Dr. Adonis Lorenzana is a Hematology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Immune Thrombocytopenic Purpura (ITP), and Classical Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Adonis Lorenzana participate in research or clinical trials?

Yes. Dr. Adonis Lorenzana has published 9 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Adonis Lorenzana's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Adonis Lorenzana accept my insurance?

Dr. Adonis Lorenzana accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 800-848-0202 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lorenzana's expertise for a condition
ConditionClose
        View All 19 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile